Medtronic’s Restore, W.L. Gore’s Tag Receive New Tech Add-On Payment
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's argument that the Restore rechargeable implantable neurostimulator represents a substantial clinical improvement over existing devices convinced CMS to award the device new technology add-on payment for fiscal year 2007
You may also be interested in...
CMS New Tech Town Hall: Industry Insists Bonus Threshold Is Too High
Boston Scientific's Wingspan intracranial stent is the only product under consideration for a new technology add-on payment in fiscal year 2008, prompting stakeholders to complain that the opaqueness of CMS' criteria for awarding the bonus payment has deterred most firms from even applying
CMS New Tech Town Hall: Industry Insists Bonus Threshold Is Too High
Boston Scientific's Wingspan intracranial stent is the only product under consideration for a new technology add-on payment in fiscal year 2008, prompting stakeholders to complain that the opaqueness of CMS' criteria for awarding the bonus payment has deterred most firms from even applying
Placebo Effect Hinders Quality Of Chronic Pain Treatment Trials – FDA, CMS
Chronic pain therapy manufacturers must meet challenges presented by the placebo effect when designing clinical trials, according to FDA and CMS